{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-23-000065","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.660087+00:00","generated_at":"2026-06-15T21:22:44.692504+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Veracyte Q1 beats: revenue $82.4M (+22%), net loss shrinks 44% to $8.1M","bullets":["Total revenue $82.4M (+22% YoY); testing revenue $72.4M (+29%); product revenue $3.9M (+31%).","Net loss improved 44% to $8.1M; diluted EPS -$0.11 from -$0.20.","Total test volume 28,788 (+24%); ended cash $177.9M near flat.","Non-GAAP gross margin 68% (vs 65%); operating expenses up 14% to $61.9M.","Enhanced Afirma test with TERT promoter testing; secured 4 new payer contracts."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-23-000065","json":"https://secwatch.observer/filing/0001384101-23-000065.json","markdown":"https://secwatch.observer/filing/0001384101-23-000065.md","text":"https://secwatch.observer/filing/0001384101-23-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410123000065/0001384101-23-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410123000065/vcyt-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:22:44.692504+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f0aef674fd5306730403fd8f9a9ace88b3999ea","claim":"VERACYTE, INC. reported the first quarter ended March 31, 2023 results: revenue $82.4 million, net income $8.1 million, EPS $0.11.","evidence_excerpt":"EX-99.1 (EX-99.1 PRESS RELEASE 05.04.2023) --- PRESS RELEASE 05.04.2023 Document Exhibit 99.1 Veracyte Announces First Quarter 2023 Financial Results Grew Total Revenue to $82.4 million, an Increase of 22% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 4, 2023 --- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1384101/000138410123000065/0001384101-23-000065-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$82.4 million"},{"label":"Net income","value":"$8.1 million"},{"label":"EPS","value":"$0.11"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}